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Abstract Endothelial cells (EC) act as leading actors in an-
giogenesis. Understanding the complex network of signal
transduction pathways which regulate angiogenesis might of-
fer insights in the regulation of normal and pathological
events, including tumours, vascular, inflammatory and im-
mune diseases. The effects of olive oil and of Blueberry ex-
tracts upon the phosphoinositide (PI)-specific phospholipase
C (PLC) enzymes were evaluated both in quiescent and in-
flammatory stimulated human umbilical vein EC (HUVEC)
using molecular biology (multiliquid bioanalysis) and immu-
nofluorescence techniques. Oleuropein significantly increased
the number of surviving HUVEC compared to untreated con-
trols, suggesting that it favours the survival and proliferation
of EC. Our results suggest that Oleuropein might be useful to
induce EC proliferation, an important event during angiogen-
esis, with special regard to wound healing. Blueberry extracts
increased the number of surviving HUVEC, although the
comparison to untreated controls did not result statistically
significant. Lipopolysaccharide (LPS) administration signifi-
cantly reduced the number of live HUVEC. LPS can also
modify the expression of selected PLC genes. Adding
Blueberry extracts to LPS treated HUVEC cultures did not
significantly modify the variations of PLC expression induced
by LPS. Oleuropein increased or reduced the expression of
PLC genes, and statistically significant results were identified
for selected PLC isoforms. Oleuropein also modified the ef-
fects of LPS upon PLC genes’ expression. Thus, our results
corroborate the hypothesis that Oleuropein owns anti-
inflammatory activity. The intracellular localization of PLC
enzymes was modified by the different treatments we used.
Podosome-like structures were observed in differently LPS
treated HUVEC.
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Introduction
During physiological and pathological events, endothelial
cells (EC) act as leading actors in angiogenesis, a complex
process in which new vessels arise from the existing vascula-
ture. During the angiogenesis process, required for develop-
ment, reproduction, wound healing, and tissue regeneration,
EC are activated through a multistep cascade (Carmeliet
2003). The morphology, gene expression and activities of
EC greatly vary depending on the neighbouring environment
(Christ and Wehling 1998, Grienddling and Alexander 1996,
Gloe and Pohl 2002). In fact, EC can react to different stimuli
with finely, sequentially tuned responses following the recruit-
ment of different signal transduction pathways. That
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contributes to the adaptation of the endothelium to different
situations and needs (Christ and Wehling 1998).
To understand the complex network of signal transduction
pathways which regulates angiogenesis might highlight the
modulation of normal and pathological events, including tu-
mours, as well as vascular, inflammatory and immune
diseases (Ferrara and Davis-Smyth 1997). That might offer a
powerful tool for novel therapeutic strategies. The
phosphoinositide (PI) specific phospholipase C (PLC) en-
zymes constitute a complex family belonging to the PI signal
transduction pathway. The PI system is involved in many cell
activities, including hormone and neurotransmitter signalling,
cell growth, membrane and cytoskeleton dynamics, ion chan-
nels activity, cell cycle, apoptosis, embryo development and
organogenesis, and cell polarity (Bunney and Katan 2011,
Comer and Parent 2007, Suh et al. 2008, Nakamura and
Fukami 2009).
A combination of compartmentalized and temporal
changes in the levels of molecules belonging to the PI
pathway, including the phosphatydil inositol bisphosphate
(PIP2), can induce a variety of cellular responses. As an
example, PIP2 regulates cytoskeleton and membrane dy-
namics, cytokinesis, nuclear events and activity of selected
ion channels (Suh et al. 2008).
PLC enzymes contribute to regulate the spatio-temporal
balance of PI molecules (Berridge and Dupont 1994,
Divecha and Irvine 1995, Hisatsune et al. 2005), cleaving
PIP2 into inositol trisphosphate (IP3) and diacylglycerol
(DAG). IP3 induces the release of calcium, a crucial mediator
in many cell/tissue activities, such as the progression through
the cell cycle, actin polymerisation and related cell migration
(Berridge and Dupont 1994; Divecha and Irvine 1995;
Hisatsune et al. 2005; Suh et al. 2008; Elsner et al. 1996;
Revest et al. 1991). DAG can be cleaved to release further
molecules acting in inflammation, such as the arachidonic
acid (AA), or can activate the protein kinases C (PKCs).
PLC enzymes can be activated by a number of different stim-
uli, which contributed to divide 13 mammalian isoenzymes
into 6 sub-families (Berridge and Dupont 1994; Suh et al.
2008). Beside the mechanisms of regulation, PLC enzymes
belonging to the same sub-family also share similarity in
aminoacids sequence, and domain organisation. Each PLC
enzyme is codified by its own gene, and alternative splicing
variants were reported for many isoenzymes (Suh et al. 2008).
The distribution of the PLC enzymes is tissue specific (Suh
et al. 2008). The panel of expression of PLCs was demonstrat-
ed to change in pathological tissues with respect to the normal
counterpart (Lo Vasco et al. 2012a, b; Lo Vasco 2011a, b, Lo
Vasco et al., 2010a, b, Lo Vasco et al. 2007, Lo Vasco et al.
2013a, b, c, Di Raimo et al. 2016).
Probably, beside the common role in the cleavage of PIP2,
each PLC enzyme bears its own functions in the modulation
of physiological and, probably, pathological responses. That
might depend on the specific mechanisms of stimulation.
These potentialities are far to be highlighted.
In our previous studies in quiescent Human Umbilical Vein
EC (HUVEC) we identified a number of PLC enzymes (Lo
Vasco et al. 2011b), although inconstantly expressed (Lo
Vasco et al. 2013a, b, c). The expression and subcellular lo-
calization of PLC enzymes varied after cells underwent differ-
ent stimuli, such as lipopolysaccharide (LPS) (Lo Vasco et al.
2013a, b, c), fibroblast growth factor (FGF) (Lo Vasco et al.
2014a) or neuropeptide Y (NPY) (Lo Vasco et al. 2014b).
Thus, our previous studies suggested that PLC enzymes were
involved in the activation of EC under different conditions,
such as inflammation, and cell growth stimulation.
In the present paper, we evaluated both in quiescent and
inflammatory stimulated HUVEC the effects upon the cell
survival and expression of PLC enzymes of olive oil, a tradi-
tional Mediterranean diet component, and of Blueberry
extracts.
Oleuropein, the main polyphenol in olive oil, was sug-
gested to play a role as protective molecule acting in cell
sufferance and death in ageing, as well as in different human
diseases, including neurodegenerative or cardiovascular pa-
thologies, cancer and diabetes (Del Rio et al. 2013, Rodrigo
et al. 2014, Stefani and Rigacci 2014, Alarcon de la Lastra
et al. 2001).
Blueberry constituents are likely to counteract oxidative
stress, decrease inflammation, and modulate both interactions
among different molecules and gene expression (Neto 2007;
Slatnar et al. 2012; Garzón et al. 2010; Duymuş et al. 2014).
Blueberries belong to Ericaceae family of berries and repre-
sent an important dietary source of bioactive compounds
(BAC) bearing antioxidant properties. The bioactive com-
pounds in berries contain phenolic compounds (phenolic
acids, flavonoids, such as anthocyanins and flavonols, and
tannins) responsible for prevention of inflammation disorders
and cardiovascular diseases (Giampieri et al. 2014a;
Giampieri et al. 2014b). The bioactive compounds also
showed protective effects to lower the risk of various cancers
(Seeram et al. 2006, Wedge et al. 2001).
Materials and methods
The following experiments were repeated at least three times.
Cell culture
HUVEC (Cambrex Corporation, Walkersville, MD –USA
were cultured as previously described (Lo Vasco et al.
2011). Endothelial Cell Growth Supplement was added to
Endogro medium (Endogro, Millipore, MA -USA).
Confluent monolayer (>60%) was obtained after 6–9 days.
Control cells were maintained for 24 h. Treated cells were
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stimulated by adding to the medium of culture respectively: i)
100 ng/ml LPS (Sigma-Aldrich, St. Louis, MO); ii)
Oleuropein 50 μM (Sigma-Aldrich); iii) Blueberry lyophi-
lized extract 40 μg/ml (see above for preparation of the ex-
tract); iv) both LPS and Oleuropein (same dosages previously
indicated); v) both LPS and Blueberry extract (same dosages
previously indicated). Both treated cells and untreated nega-
tive controls, previously plated on six-well plates, were then
suspended in TRIzol reagent (Invitrogen Corporation,
Carlsbad, CA) and checked after 3, 6, and 24 h.
The lyophilized powder of Blueberry was prepared as pre-
viously described (Li et al. 2013; Cesa et al. 2017). Briefly,
fresh and fully ripe Blueberry fruits coming from the Trentino
region of Italy were washed, dried on paper and homogenized
at room temperature for 2 min either by a domestic mixer at
16000 rpm or by a T18 Ultra-Turrax® homogenizer (IKA®,
Staufen, Germany) at 10000 rpm. As previously described (Li
et al. 2013), the resulting fruit puree was heated at 70 °C for
2 h and rapidly ice-cooled. Then, the mix of anthocyanins was
extracted. The homogenates were stirred with 50 mL of etha-
nol:0.5% acetic acid (70:30, v/v) (Carlo Erba Milan, Italy)
(Fluka, Milan, Italy). The suspension was centrifuged at
12000 g for 10 min at 4 °C. The collected supernatant was
concentrated under reduced pressure at 40 °C with a rotary
evaporator and added with ethanol:0.5% acetic acid (70:30, v/
v) to a final volume of 20 ml. The extraction was checked by
HPLC analysis by using Perkin-Elmer apparatus equipped
with a series LC 200 pump, a series 200 diode array detector
and a series 200 autosampler; data were acquired with Perkin-
Elmer Totalchrom software. In each sample, the following
anthocyanins were identified: delphinidin-3-O-galactoside
(del-3-gal), cyanidin-3-O-galactoside (cya-3-gal),
delphinidin-3-O-arabinoside (del-3-ara), petunidin-3-O-
galactoside (pet-3-gal), cyanidin-3-O-arabinoside (cya-3-
ara), petunidin-3-O-arabinoside (pet-3-ara), malvidin-3-O-
galactoside (mal-3-gal), malvidin-3-O-glucoside (mal-3-glu)
and malvidin-3-O-arabinoside (mal-3-ara) (Cesa et al. 2017).
MTT test
The cell viability was evaluated using colorimetric microassay
(Mosmann 1993). Briefly, tetrazolium salt (MTT: 3-[4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide, 5 mg/
ml suspended in PB) (Sigma) was added to cell cultures and
then incubated for 4 h. The plates were read with a multiwell
scanning Elisa reader (wavelength 540 nm, reference length
630 nm) (Biorad Laboratories, Hercules, CA, USA). The rel-
ative absorbance was expressed as a percent of the corre-
sponding control and calibrated against control cell cultures
plated at different densities, which were then counted in a
Coulter ZM cell counter equippedwith Channelyser to control
for dead cells. The accuracy of theMTTmethodwas shown to
be +/−200 cells as previously described (Mosmann 1993).
RT-PCR and molecular biology experiments (Multiliquid
bioanalysis)
The experiments were conducted after 24 h from treatment
(T0 = seeding time).
HUVEC, both treated and untreated controls, were plated
on six-well plates, and suspended in TRIzol reagent
(Invitrogen Corporation, Carlsbad, CA, USA) 3, 6 and 24 h
after addiction to the medium of culture respectively of: i)
100 ng/ml LPS; ii) Oleuropein 50 μM; iii) Blueberry lyophi-
lized extract 40 μg/ml; iv) LPS plus Oleuropein; v) LPS plus
Blueberry extract. Total RNAwas isolated from samples fol-
lowing the manufacturer’s instructions. The obtained RNA
purity was assessed by using a UV/visible spectrophotometer
(SmartSpec 3000, Biorad Laboratories). Total RNA (1 mg)
was reverse transcribed by using High Capacity cDNA
Reverse Transcription Kit (Applied Byosystems, Carlsbad,
CA) according to manufacturer’s instructions. Briefly, RT
Buffer, dNTP Mix, RT Random Primers, Multiscribe
Reverse Transcriptase, RNase Inhibitor and DEPC-treated
distilled water were added in RNase free tubes on ice. RNA
sample was added. Thermal cycler program was: 25 °C for
10 min; 37 °C for 120 min; the reaction was stopped at 85 °C
for 5 min. The final volume was 20 ml. For PCR reactions, the
primer pairs (Bio Basic Inc., Amherst- NY, USA) used for
PLC isoenzymes are listed in Table 1.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
OMIM *138400) housekeeping gene was used as a positive
control. The following primer pairs for GAPDH were used
(Bio Basic Inc) forward 5 ′-CGAGATCCCTCCAA
AATCAA-3 ′ and reverse 5 ′-GTCTTCTGGGTGGC
AGTGAT-3′. The specificity of all primers was verified
searching in NCBI data base possible homology to cDNAs
of unrelated proteins. Positive control cells (osteosarcoma
HS888 cells) were used to check the efficacy of the primers
for PLCD4 and PLCE.
Each PCR tube contained the following reagents: 0.2 μM
of both sense and antisense primers, 1–3 μl (about 1 μg) tem-
plate cDNA, 0.2 mM dNTP mix, 2.5 U REDTaq Genomic
DNA polymerase (Sigma, Germany) and 1X reaction buffer.
MgCl2 was added at variable (empirical determination by
setting the experiment) final concentration. The final volume
was 50 μl. The amplification was started with an initial dena-
turation step at 94 °C for 2 min and was followed by 35 cycles
consisting of denaturation (30 s) at 94 °C, annealing (30 s) at
the appropriate temperature for each primer pair and extension
(1 min) at 72 °C. The PCR products were analysed by 1.5%
TAE ethidium bromide stained agarose gel electrophoresis
(Agarose Gel Unit, Biorad Laboratories Inc., UK). PC-
assisted CCD camera UVB lamp (Vilber Lourmaret, France)
was used for gel documentation. Gel electrophoresis of the
amplification products revealed single DNA bands with nu-
cleotide lengths as expected for each primer pair. Optical
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densities were normalised to the mRNA content of GAPDH.
To exclude possible DNA contamination during the RT-PCR,
RNA samples were amplified by PCR without reverse tran-
scription. No band was observed, confirming no DNA con-
tamination in the RNA preparation procedure (data not
shown). We measured mRNA concentrations as follows: in
untreated HUVEC we measured the basal (t = 0) concentra-
tion, and after 3, 6 and 24 h to evaluate the effects of the
progression of the cell cycle upon transcription. In HUVEC
treated with different molecules (LPS, Oleuropein, Blueberry
extract), we measured mRNA concentration after 3, 6 and
24 h. The PCR products were analysed and quantified with
the Agilent 2100 bioanalyzer using the DNA 1000 LabChip
kit (Agilent Technologies, Germany). All the experiment sets
were repeated at least three times.
Immunofluorescence
Immunofluorescence analysis of HUVEC was used to evalu-
ate the sub-cellular distribution of PLC enzymes in control
HUVEC, in LPS treated HUVEC, in HUVEC treated with
LPS and Blueberry extract and in HUVEC treated with LPS
and Oleuropein. Briefly, cells were washed three times with
PBS and fixed with 4% paraformaldehyde (PFA) in phosphate
buffer saline (PBS) for 10 min at 4 °C, then three washes with
PBS followed. Cells were incubated with primary antibodies
diluted in PBS for 1 h at room temperature. Cover-slips were
then incubated with the specific secondary antibody Texas
Table 1 List of PLC primers for PCR experiments
PLCB1 OMIM *607120 forward 5′-AGCTCTCAGAACAAGCCTCCAACA-3’
reverse 5′-ATCATCGTCGTCGTCACTTTCCGT-3’
PLCB2 OMIM *604114 forward 5′-AAGGTGAAGGCCTATCTGAGCCAA-3’
reverse 5′-CTTGGCAAACTTCCCAAAGCGAGT-3’
PLCB3 OMIM *600230 forward 5′-TATCTTCTTGGACCTGCTGACCGT-3’
reverse 5′-TGTGCCCTCATCTGTAGTTGGCTT-3’
PLCB4 OMIM *600810 forward 5′-GCACAGCACACAAAGGAATGGTCA-3’
reverse 5′-CGCATTTCCTTGCTTTCCCTGTCA-3’
PLCG1 OMIM *172420 forward 5′-TCTACCTGGAGGACCCTGTGAA-3’
reverse 5′-CCAGAAAGAGAG CGTGTAGTCG-3’
PLCG2 OMIM *600220 forward 5′-AGTACATGCAGATGAATCACGC-3’
reverse 5′-ACCTGAATCCTGATTTGACTGC-3’
PLCD1 OMIM *602142 forward 5′-CTGAGCGTGTGGTTCCAGC-3’
reverse 5′-CAGGCCCTCGGACTGGT-3’
PLCD3 OMIM *608795 forward 5′-CCAGAACCACTCTCAGCATCCA-3’
reverse 5′-GCCATTGTTGAGCACGTAGTCAG-3’
PLCD4 OMIM *605939 forward 5′-AGACACGTCCCAGTCTGGAACC- 3’
reverse 5′-CTGCTTCCTCTTCCTCATATTC- 3
PLCE OMIM *608414 forward 5′-GGGGCCACGGTCATCCAC-3’
reverse 5′-GGGCCTTCATACCGTCCATCCTC-3’
PLCH1 OMIM *612835 forward 5′-CTTTGGTTCGGTTCCTTGTGTGG-3’
reverse 5′-GGATGCTTCTGTCAGTCCTTCC-3’
PLCH2 OMIM *612836 forward 5′-GAAACTGGCCTCCAAACACTGCCCGCCG-3’
reverse 5′-GTCTTGTTGGAGATGCACGTGCCCCTTGC-3’
GAPDH GAPDH forward 5′-CGAGATCCCTCCAAAATCAA-3’
reverse 5′-GTCTTCTGGGTGGCAGTGAT-3’
Vil2 Vil2 forward 5′ - GCTGTGCAGGCCAAGTTT-3’
reverse 5′ -TCCCACTGGTCC CTGGTA-3’
Table 2 Survival of cells. Media of the results
T0 3h 6h 24h
192.333
Ctrl 82.500 83.958 73.333
Oleuropein 142.083 162.083 193.333
Blueberry 120.833 121.250 196.667
Lps 71.667 95.417 95.833
Lps + Oleuropein 122.500 140.417 159.583
Lps + Blueberry 63.750 115.833 165.000
Ctrl = controls (untreated cells). T0 = seeding of cells
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Red or fluorescein-conjugated for 1 h at room temperature.
The primary anti-human PLC antibodies and the appropriated
fluorescence conjugated secondary antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Cells were
washed twice with 1X PBS 5 min, then counterstained with
4′,6-diamidino-2-phenylindole (DAPI) fluorescent staining to
detect the cell nuclei. The slides (2 well μ-slides) (Ibidi,
Germany) were visualized and captured with an Olympus
IX50 inverted fluorescence microscope (Olympus, Tokyo,
Japan) and processed using Adobe Photoshop 7.0 software.
Results
Effects of treatments upon HUVEC survival (MTT test)
The media of results of all the sets of experiments were listed
in Tables 2 and 3. The experiments were repeated three times
for each observation period (0, 3, 6 and 24 h) and for each
treatment. Mathematical media was calculated.
In control HUVEC the survival rate was 42.9% after 3 h.
After 6 h, the surviving cells’ number slightly increased
1.74% (43.65% of the initial controls). After 24 h, the surviv-
ing cells’ number further reduced about 12.65% (38.1% of the
initial controls) (Fig. 1; Table 2).
After oil treatment, the survival rate of HUVEC was sig-
nificantly higher than controls after 3, 6 and 24 h (Fig. 1;
Table 2). Comparison of the survival rates of controls and
oil treated HUVEC with ANOVA analysis resulted statistical-
ly significant with p-value = .004921 (Table 3).
After Blueberry extract treatment, the survival rate of
HUVEC was higher than controls after 3 and 6 h and even
higher after 24 h (Fig. 1; Table 2). Comparison of the survival
rates of controls and HUVEC treated with Blueberry extracts
with ANOVA analysis did not result statistically significant
with p-value = .059531 (Table 3).
After LPS treatment, the survival rate of HUVEC
was markedly reduced after 3 h. The number of cells
slightly increased after 6 h and stayed about the same
after 24 h (Fig. 1; Table 2). Comparison of the survival
rates of controls and LPS treated HUVEC with ANOVA
analysis did not result statistically significant with p-
value = .423272 (Table 3).
After combined treatment with both LPS and Oleuropein,
the number of surviving cells was slightly reduced after 3 h,
while it slightly and progressively increased after 6 and 24 h
(Fig. 1; Table 2). Comparison of the survival rates of controls
and oil treated HUVEC resulted statistically significant with
p-value = .005572 (Table 2).
After combined treatment with both LPS and Blueberry
extract, the number of surviving cells was markedly reduced,
although it progressively increased after 6 and 24 h (Fig. 1).
Comparison of the survival rates of controls and oil treated
HUVEC with ANOVA analysis did not result statistically sig-
nificant with p-value = .300808 (Table 3).
The overall analysis of the results with ANOVA analysis of
statistical variation resulted statistically significant with a p
value = 0.0294 (Table 3).
RT-PCR
The results are listed in Table 4. The multiliquid bioanalysis
was conducted after 24 h from each treatment. PLCD4 and
PLCE were not expressed both in control and treated
Table 3 Comparison of





Ctrl vs LPS 0.423272
Ctrl vs LPS + Blueberry
extract
0.300808
Ctrl vs LPS + Oleuropein 0.004921
Ctrl vs Blueberry extract 0.059531
Ctrl vs Oleuropein 0.004921
Ctrl vs treated HUVEC 0.0294
P value was considered significant when
<.05
Fig. 1 Histogram of HUVEC
survival after 3, 6 and 24 h.
T0 = seeding time. On y axis:
CTRL = untreated HUVEC.
OL = HUVEC treated with
Oleuropein. BB = HUVEC
treated with Blueberry extract.
LPS/OL = HUVEC treated with
LPS plus Oleuropein. LPS/
BB = HUVEC treated with LPS
plus Blueberry extract. On x axis:
number of live HUVEC. Standard
error bars are indicated
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HUVEC. In positive control cells (osteosarcoma HS888 cells)
both PLCD4 and PLCE were detected, as expected (data not
shown).
All the treatments slightly increased the expression of
GAPDH in a statistically non-significant measure (Tables 3
and 4). All the treatments blocked the expression of PLCH1
(Table 4). As the expression of PLCH1 in HUVEC controls is
low, that observation did not result statistically significant
(Table 5).
Different LPS treatments. Administration of LPS to
HUVEC cultures blocked the expression of PLCB2 and
PLCG2; reduced the expression of PLCB1, PLCB4,
PLCD1, PLCD3, PLCG1 PLCH2 and increased the expres-
sion of PLCB3 (Table 4). The reduction of expression resulted
statistically significant for the following genes: PLCB2,
PLCD3, PLCG1 and PLCG2 (Table 4). Adding LPS and
Blueberry extracts to the cultures blocked the expression of
PLCB1 and PLCG2; reduced the expression of PLCB2,
PLCB4, PLCD1, PLCD3 and PLCG1 and increased the ex-
pression of PLCB3 and PLCH2 (Table 3). The reduction re-
sulted statistically significant for PLCB1 and PLCG2
(Table 5). Adding LPS and Oleuropein to HUVEC cultures
blocked the expression of PLCB2; reduced the expression
of PLCD3, PLCG1 and PLCH2 and increased the expres-
sion of PLCB1, PLCB3, PLCB4, PLCD1 and PLCG2
(Table 4). The increase resulted statistically significant
for PLCB3 and PLCG2.
Blueberry extract. Administration of Blueberry extract to
HUVEC cultures reduced the expression of PLCB1, PLCB2,
PLCB4, PLCD3, PLCG1, PLCG2 and PLCH2, and increased
the expression of PLCB3 and PLCD1 (Table 4). However, the
variation of PLC genes’ expression induced by Blueberry ex-
tract did not result statistically significant (Table 5).
Oleuropein. Administration of Oleuropein to HUVEC cul-
tures reduced the expression of PLCB2, PLCD3 and PLCH2
and increased the expression of PLCB1, PLCB3, PLCB4,
PLCD1, PLCG1 and PLCG2 (Table 4). The reduction of
PLCH2 expression and the increase of PLCD1 expression
resulted statistically significant.
Immunofluorescence
Control HUVEC cells. PLCβ1 was detected in the cytoplasm,
with granule distribution. PLC β2 was detected in the nucleus
(Fig. 2). PLC β3 was detected in the nucleus and in the cyto-
plasm nearby the perinuclear area (Fig. 2). PLC β4 was de-
tected in a limited number of cells, partly in the nucleus and
cytoplasm, partly in the cytoplasm (Fig. 2). PLC δ4 was de-
tected in the nucleus (Figure 3). PLC ε was detected in the
nucleus and enhanced in the nuclear membrane (Fig. 3). PLC
γ1 was detected in the cytoplasm with granule distribution
(Fig. 4). PLC η1 was detected in the nucleus; it was also
detected in the cytoplasm, with granule distribution (Fig. 4).
Table 4 Media of results of Multiliquid Bioanalysis of PCR products for PLC genes
PLCB1 PLCB2 PLCB3 PLCB4 PLCD1 PLCD3 PLCG1 PLCG2 PLCH1 PLCH2 GAPDH
Ctrl 3.78 3.69 4.28 2.03 4.46 7.33 9.59 1.2 1.85 0.7 4.2
Blueberry 2.58 2.85 4.99 0.92 4.84 2.45 5.37 0.9 0 0.58 5.77
Oleuropein 4.48 1.44 7.01 4.89 8.27 1.64 13.4 3.41 0 0.03 4.73
LPS 3.01 0 5.73 0.65 3.95 1.56 1.09 0 0 0.38 5.23
LPS + Blueberry 0 0.44 5.75 1.43 3.84 2.33 5.12 0 0 0.95 4.73
LPS + Oleuropein 4.77 0 7.57 3.2 6.52 2.27 9.04 1.89 0 0.55 5.43
Ctrl: control HUVEC. Blueberry: HUVEC treated with Blueberry Extract. Oleuropein: HUVEC treated with Oleuropein. LPS: HUVEC treated with
LPS. LPS + Blueberry: HUVEC treated with LPS plus Blueberry extract. LPS + Oleuropein: HUVEC treated with LPS plus Oleuropein
Table 5 Effects of different treatments upon the expression of PLC genes. P value of rates between controls and differently treated HUVEC
PLCB1 PLCB2 PLCB3 PLCB4 PLCD1 PLCD3 PLCG1 PLCG2 PLCH1 PLCH2 GAPDH
Ctrl/LPS .366552 .006836 .230904 .137551 .416028 .028575 .011501 .035265 .148333 .272629 .212646
Ctrl/LPS+BB .045171 .129659 .287836 .355426 .41734 .144955 .241 .035265 .148333 .35068 .313054
Ctrl/LPS+O .395257 .101851 .011789 .275052 .192242 .142552 .466665 .019326 .148333 .427823 .182645
Ctrl/BB .300695 .401299 .378535 .228635 .44561 .150193 .265179 .252186 .148333 .446458 .10019
Ctrl/O .369124 .217272 .101051 .116759 .027475 .118864 .298076 .242198 .148333 .017749 .318127
Numbers in italic bold mark the statistically significant results
Ctrl/ LPS: Control HUVEC versus LPS treated HUVEC. Ctrl/ LPS + BB: Control HUVEC versus HUVEC treated with LPS plus Blueberry Extract.
Ctrl/ LPS +O: Control HUVECversus HUVEC treatedwith LPS plus Oleuropein. Ctrl/ BB: Control HUVEC versus Blueberry Extract treated HUVEC.
Ctrl/ O: Control HUVEC versus Oleuropein treated HUVEC
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PLC η2 was detected in the perinuclear area (figure 4). PLC
δ1, PLC δ3 and PLC γ2 were not detected (Figs. 3 and 4).
LPS treated HUVEC. PLC β1 was detected in the cyto-
plasm, with fine granule distribution, and in podosome-like
structures (Fig. 2). PLC β3 was detected in the perinuclear
area cytoplasm (Fig. 2). PLC β4 was detected in the nucleus
and cytoplasm in a limited number of cells, while it was de-
tected exclusively in the cytoplasm in the remaining cells
(Fig. 2). PLC δ3 and PLC γ1 were detected in the nucleus
(Figs. 3 and 4). PLC η1 was weakly visible in the nucleus,
while it was detected in the perinuclear area (Fig. 4). PLC η2
was detected in the nucleus and in cell evaginations reaching
out from cell to cell (Figs. 4 and 5). PLC β2, PLC δ1, PLC δ4,
PLC ε and PLC γ2 were not detected (Figs. 2, 3 and 4).
HUVEC treated with both LPS and Blueberry extracts.
PLC β1 was detected in the cytoplasm, with granule
Fig. 2 Immunofluorescence of
PLC enzymes of the β subfamily.
CTRL = control HUVEC;
LPS = LPS treated HUVEC; LPS/
BB = HUVEC treated with LPS
plus Blueberry extract; LPS/
O = HUVEC treated with LPS
plus Oleuropein. For description,
please see the results section
Fig. 3 Immunofluorescence of
PLC enzymes of the δ subfamily
and of PLC ε. CTRL = control
HUVEC; LPS = LPS treated
HUVEC; LPS/BB = HUVEC
treated with LPS plus Blueberry
extract; LPS/O = HUVEC treated
with LPS plus Oleuropein. For
description, please see the results
section
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distribution particularly dense around the nucleus (Fig. 2).
PLC β2 was weakly detected in the cytoplasm (Fig. 2). PLC
β3 was weakly detected in the cytoplasm, particularly evident
in the perinuclear area (Fig. 2). PLC β4 and PLC δ1 were
weakly detected in the cytoplasm (Fig. 2 and 3). PLC ε was
detected in the nucleus; it was also detected in the perinuclear
area of the cytoplasm (Fig. 3). PLC γ1 and PLC γ2 were
detected in the nucleus v. PLC η1 was detected in the cyto-
plasm (Fig. 4). PLC η2 was detected in the nucleus, in the
cytoplasm with a submembrane enhancement and in
podosome-like structures (Figs. 4 and 5). PLC δ3 and PLC
δ4 were not detected (Fig. 3).
HUVEC treated with both LPS and Oleuropein. PLC β1
was detected in the cytoplasm with fine granule distribution
(Fig. 2). PLC β2 was detected in the perinuclear area with fine
granule distribution (Fig. 2). PLC β3 was detected in the cy-
toplasm, particularly dense in the perinuclear area (Fig. 2).
PLC β4 was weakly detected in the cytoplasm (Fig. 2). PLC
ε was detected in the nucleus and weakly in the cytoplasm
(Fig. 3). PLC γ1 was detected in the nucleus and in the
Fig. 4 Immunofluorescence of
PLC enzymes of the γ and η
subfamilies. CTRL = control
HUVEC; LPS = LPS treated
HUVEC; LPS/BB = HUVEC
treated with LPS plus Blueberry
extract; LPS/O = HUVEC treated
with LPS plus Oleuropein. For
description, please see the results
section
Fig. 5 Immunofluorescence of
PLC β1 (upper images) in LPS
treated HUVEC and of PLC η2
(lower images) in HUVEC treated
with LPS plus Blueberry extracts.
Presence of the enzymes in
podosome-like structures
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perinuclear area, where it seems to be particularly concentrat-
ed (Fig. 4). PLC γ2 and PLC η2 were detected in the nucleus
and in the perinuclear region of the cytoplasm (Fig. 4). PLC
η1 was detected in the cytoplasm with granule distribution
(Fig. 4). PLC δ1, PLC δ3 and PLC δ4 were not detected
(Fig. 3).
Discussion
Our present results indicate that Oleuropein administration to
HUVEC cultures increased the number of surviving cells
compared to untreated controls. Notably, Oleuropein signifi-
cantly reduces the cell death rate after seeding (Fig. 1;
Table 2). The administration of Blueberry extracts also in-
creased the number of HUVEC, however the results were
not statistically significant (Tables 2 and 3).
Confirming our previous works (Lo Vasco et al.
2007; Lo Vasco et al. 2013a, b, c), LPS administration
to HUVEC cultures significantly reduced the number of
live cells, especially in the 0–3 h interval (Fig. 1,
Tables 2 and 3). That suggests how inflammation affects
HUVEC survival especially briefly after stimulation.
Although the combination of LPS plus Oleuropein treat-
ment reduced the number of surviving HUVEC with
respect to untreated controls, the number of live cells
was greater compared to LPS treated HUVEC. That
might suggest that Oleuropein can modulate the effect
of LPS upon cell survival, reducing the number of dead
cells. The combination of LPS and Blueberry extract
treatment did not significantly modify the effects of
LPS treatment alone.
Therefore, Oleuropein seems to favour the survival and
proliferation of quiescent HUVEC and to reduce the cell death
rate induced by LPS. That confirms the anti-inflammatory role
of Oleuropein. Our results suggest that Oleuropein might be
useful to induce EC proliferation, an important event during
angiogenesis, with special regard to wound healing.
The present results confirm our previous observations (Lo
Vasco et al. 2007, Lo Vasco et al., 2010a, b; Lo Vasco et al.,
2012a, b; Lo Vasco et al. 2013a, b, c) that LPS can modify the
expression of some PLC genes. Adding Blueberry extracts to
LPS treated HUVEC cultures did not significantly modify the
variations of PLC expression induced by LPS. However, for
selected PLC genes, the administration of Blueberry seems to
slightly reduce the effects of LPS. In fact, LPS reduced the
expression of a number of PLC genes, while adding Blueberry
extract to LPS the reduction was less evident (Table 3). That is
a surprising observation, in that Blueberry extract alone also
reduced the expression of the same genes. However, those
results were not statistically significant and further studies
are required in order to evaluate the controversial effects of
contemporary administration of LPS and Blueberry extract.
All the treatments increased the expression of PLCB3 con-
temporarily reducing the expression of PLCD3. Although no
explanation is currently possible, that might represent an in-
teresting observation requiring further analysis addressed to
evaluate the possible relationship between the expression of
these two genes.
Oleuropein increased or reduced the expression of PLC
genes, and statistically significant results were identified for
PLCD1 and PLCH2. Moreover, Oleuropein could modify the
effects of LPS upon PLC genes’ expression. The expression of
PLCB1, PLCB3, PLCB4, PLCD1 and PLCG1 were respec-
tively reduced by LPS and increased by Oleuropein. Adding
contemporarily Oleuropein and LPS to HUVEC cultures at-
tenuated the LPS induced reduction of genes’ expression
(Table 3). For PLCG2, this effect was more evident. In fact,
the expression of PLCG2 was blocked by LPS, as well as by
LPS plus Blueberry extract. In presence of LPS plus
Oleuropein, PLCG2 was measured and its expression was
increased with respect to untreated control HUVEC.
Oleuropein administration markedly increased the expression
of PLCG2 (Table 2 and 3).
Other genes, such as PLCB2, PLCD3 and PLCH2 also
deserve comments. The expression of those genes was re-
duced both by LPS and Oleuropein treatment. However, the
contemporary administration of LPS and Oleuropein induced
a milder reduction of PLCD3 and PLCH2 with respect to
controls. On the contrary, the expression of PLCB2 was
blocked by LPS treatment and reduced by Oleuropein treat-
ment. The expression of PLCB2 was blocked by the contem-
porary administration of LPS and Oleuropein, suggesting that
Oleuropein did not efficiently counteract the effects of LPS
upon this gene.
Therefore, our present results confirm that the regulation of
PLC genes’ expression is crucial in the inflammatory activa-
tion of HUVEC. Our results indicate that in HUVEC selected
PLC genes, namely PLCB1, PLCB3, PLCB4, PLCD1 and
PLCG1 behave oppositely under LPS or Oleuropein
stimulation.
In previous reports, PLC β1 was involved in inflammatory
stimulation, both in HUVEC (Lo Vasco et al. 2013a, b, c) and
in astrocytes (Lo Vasco et al. 2010a), in a complex manner,
not completely highlighted. Moreover, PLC β1 was down-
regulated in endometriosis compared to normal endometrium
(Lo Vasco et al. 2012a, b). PLC β3 was also claimed to be
affected with inflammatory stimulation. In fact, PLC β3
underwent down-regulation during astrocyte LPS-activation
(Lo Vasco et al., 2010a, b) and up-regulation in endometriosis
(Lo Vasco et al. 2012a, 2012b).
Previous studies indicated that PLC γ isoforms are in-
volved in the inflammatory activation of macrophages (Di
Raimo et al. 2016). PLC γ subfamily is activated in the pres-
ence of AA that serves as a common link between receptor
activation of Phospholipase A2 and the PI pathway (Suh et al.
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2008). PLC γ isoforms are also involved in the activation of
EC by the vascular endothelial growth factor (VEGF) via its
receptor VEGFR-2 (Baker et al. 2009). Plc γ1 was suggested
to be involved in astrocyte LPS-induced activation (Lo Vasco
et al. 2010a). Literature data demonstrated PLC γ1 to be es-
sential for T cell development, activation and tolerance. In
fact, in both in vitro and animal models PLC γ1 affects the
activities of regulatory T cells, causing inflammatory/
autoimmune symptoms (Kalra et al. 2004; Fu et al. 2010).
The involvement of PLC δ1 in inflammatory diseases was
also suggested. In fact, PLC δ1 isoform was down-regulated
in endometriosis (Lo Vasco et al. 2012a, 2012b) and lack of
the Plcd1 gene in knock-out (KO) mice induces skin inflam-
mation (Suh et al. 2008).
Beside confirming the recruitment after inflammatory stim-
ulation, our findings suggest that the expression of PLC genes
can be finely regulated by using anti-inflammatory molecules.
Our results suggest that Oleuropein can affect the LPS in-
duced modifications of PLC expression. That supports the
hypothesis of a possible role as a modulation molecule which
can regulate the expression of signalling elements during in-
flammation. This observation paves the way to novel insights
to the regulation and the possible therapeutic use of signalling
molecules in the control of the inflammation cascade.
The intracellular localization of PLC enzymes was also
modified by different treatments (Figs. 2, 3 and 4). The trans-
location of PLC enzymes from cytoplasm to nucleus and vice
versa was reported and might depend on the cell cycle (Suh
et al. 2008). The present results indicate that PLC γ1 and PLC
η1 enzymes were located within the cytoplasm of untreated
HUVEC and in the nucleus of LPS treated HUVEC (Fig. 4).
Although the mRNA for PLCD4 gene was not detected, the
corresponding protein PLC δ4 was detected in the nucleus of
untreated HUVEC, while it was not detected in LPS treated
HUVEC (Fig. 3). PLC γ2 was not detected in both untreated
HUVEC and LPS treated HUVEC. Surprisingly, PLC γ2 was
detected in the nuclei of HUVEC treated with LPS plus
Blueberry extract, as well as in the perinuclear halo of
HUVEC cells treated with LPS plus Oleuropein (Fig. 4).
We also observed podosome-like structures in differently
LPS treated HUVEC (Fig. 5). Interestingly, in podosomes we
detected PLC β1 and PLC η2. Migration and invasion of EC
are the trigger point of vessels’ formation and integrity (Osiak
et al. 2005). Podosomes are specialized microdomains of the
plasma membrane consisting of a complex structure with a
central actin core (Rottiers et al. 2009). Exclusively intact
EC can form podosomes. During cell migration, podosomes
are supposed to confer adhesive and invasive properties to
cells. RhoGTPases and Src kinase signalling regulate the cy-
toskeleton and, probably, the migration/invasion process.
Interestingly, PLC β enzymes are regulated by heterotrimeric
GTP-binding proteins as well as PLC η enzymes are activated
through GPCR stimulation (Suh et al. 2008). Therefore, the
presence of both PLCβ1 and PLC η2 in HUVEC podosomes,
which might indicate the involvement in cytoskeleton remod-
eling, will require further investigations.
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